News | September 28, 2022

Eurofins Genoma Announces Launch Of niPGT-A, A Non-Invasive, Embryo Biopsy Free, Preimplantation Genetic Aneuploidy Screening Test

Eurofins Genoma, part of the Eurofins network of companies, and a diagnostic partner for genetic, cytogenetic and molecular analyses, and one of the most advanced European molecular diagnostics laboratories, announces the launch of niPGT-A, a non-invasive preimplantation genetic aneuploidy screening test.

Preimplantation genetic testing for aneuploidy (PGT-A) plays an important role in Assisted Reproductive Technology (ART) applications, as it allows medical practicioners to assess the chromosonal make up of in vitro fertilisation (IVF) embryos and, as such, determine chromosonal abnormalities which may lead to complications during pregnancy. Although an incredibly useful tool, PGT-A testing is underutilised globally because of a number of limiting factors, including access to specialised staff to carry out the required embryo biopsy, or a requirement for investment in specific testing or technological equipment.

Eurofins Genoma’s non-invasive PGT-A for aneuploidy screening (niPGT-A) provides IVF centres with access to a highly accurate alternative to traditional PGT-A testing, producing quality embryo samples and avoiding the need for embryo biopsies. PGT-A utilises embryonic cell-free DNA (cfDNA) to evaluate embryo ploidy. It yields representative data on the embryo in its entirety, deriving DNA from whole embryonic cells, both the trophectoderm and inner cell mass, rather than limited cell numbers analysed through biopsy.

Eurofins Genoma is a pioneer in non-invasive pre-natal testing (NIPT) in Italy, and is an industry leader in innovative diagnostic tests in oncology. The launch of niPGT-A is representative of Eurofins Genoma’s commitment to innovation and development of new tests to meet the diverse diagnostic needs in the field of reproductive genetics.

For more information, visit

Source: Eurofins Scientific